Introduction:

Multiple myeloma is a neoplasm characterized by the presence of a plasmatic cells clone; accounts for 1 % of cancers, and approximately 10 % of hematologic malignancies. High dose chemotherapy followed by autologous stem cell transplantation remains a safe option in selected patients.

Objective:

To analyze the results of autologous stem cell transplantation from peripheral blood in patients with multiple myeloma.

Methods:

A descriptive, longitudinal, ambispective study. The universe was by 14 patients (13 of them were finally included), with diagnosis of multiple myeloma treated with autologous stem cell transplantation from peripheral blood at Institute of Hematology and Immunology of Havana from January 2014 to December 2019.

Results:

The median age of the patient was 53.9±5.6 years, with predominance of female sex. More frequents complications were infections and mucositis. A year overall survival was 100 % and 80 % at five years. Progression free survival at one and five years was 83% and 73%, respectively.

Conclusions:

The autologous stem cell transplantation in multiple myeloma patients increase complete responses, overall survival and progression free survival and is well accepted without severe complications.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )